Race and long-acting antipsychotic prescription at a community mental health center: A retrospective chart review

Journal of Clinical Psychiatry

Volumn 73, Issue 4, 2012, Pages 513-517

  Aggarwal, Neil Krishan ^a   Rosenheck, Robert A ^b   Woods, Scott W ^a   Sernyak, Michael J ^a  

^a Yale University School of Medicine   (United States)

^b VA New England Mental Illness Research and Education Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AFRICAN AMERICAN; BIPOLAR DISORDER; CAUCASIAN; COMMUNITY CARE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DSM-IV; ETHNICITY; FEMALE; HEALTH CARE DISPARITY; HEALTH CARE PRACTICE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL RECORD REVIEW; MENTAL HEALTH CARE; MINORITY GROUP; MOOD DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RACE DIFFERENCE; RETROSPECTIVE STUDY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL STATUS; SUBSTANCE ABUSE;

EID: 84860550103     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07161     Document Type: Review

References (26)

1. Committee on Future Directions for the National Healthcare Quality and Disparities Report. Future directions for the National Healthcare Quality and Disparities Reports. Institute of Medicine Web site. http://www.iom.edu/Reports/ 2010/Future-Directions-for-the-National-Healthcare-Quality-and-Disparities- Reports.aspx. Updated April 14, 2010. Accessed December 21, 2011.
2. Satcher D. Mental health: culture, race, and ethnicity - a supplement to mental health: a report of the Surgeon General. Surgeon General's Web site. http://www.surgeongeneral.gov/library/mentalhealth/cre/sma-01-3613.pdf. Updated 2001. Accessed December 21, 2011.
3. Strakowski SM, Lonczak HS, Sax KW, et al. The effects of race on diagnosis and disposition from a psychiatric emergency service. J Clin Psychiatry. 1995;56(3):101-107. PubMed
4. Swanson J, Swartz M, Van Dorn RA, et al. Racial disparities in involuntary outpatient commitment: are they real? Health Aff (Millwood). 2009;28(3):816-826. doi:10.137/hlthaf.28.3.816 PubMed
5. Price N, Glazer W, Morgenstern H. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry. 1985;142(12):1491-1492. PubMed (Pubitemid 16169894)
6. Arnold LM, Strakowski SM, Schwiers ML, et al. Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res. 2004;66(2-3):169-175. doi:10.1016/S0920-964(03)0102-6 PubMed (Pubitemid 38041116)
7. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry. 2002;159(4):567-572. doi:10.176/api.ajp.159.4.567 PubMed (Pubitemid 34274938)
8. Kreyenbuhl J, Zito JM, Buchanan RW, et al. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003;29(2):183-193. PubMed (Pubitemid 37187683)
9. Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58(4):482-488. doi:10.176/api.ps.58.4. 482 PubMed (Pubitemid 46640638)
10. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002;28(1):17-29. PubMed (Pubitemid 34534747)
11. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995-1001. doi:10.1093/schbul/sbm137 PubMed
12. Owen RR, Fischer EP, Kirchner JE, et al. Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Am J Med Qual. 2003;18(4):140-146. doi:10.17/10628606030180402 PubMed (Pubitemid 37026133)
13. Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry suppl. 2009;195:S37-S42. doi:10.192/bjp.195.52.s37 PubMed
14. Humes KR, Jones NA, Ramirez RR. Overview of race and Hispanic origin: briefs. United States Census Bureau Web site. http://www.census.gov/prod/ cen2010/briefs/c2010br-02.pdf. Updated March 2011. Accessed December 21, 2011.
15. Aggarwal NK, Sernyak MJ, Rosenheck RA: Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting intramuscular antipsychotic medications. J Clin Psychopharmacol. In press.
16. Glazer WM. Who receives long-acting antipsychotic medications? Psychiatr Serv. 2007;58(4):437. doi:10.176/api.ps.58.4.437 PubMed (Pubitemid 46640629)
17. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry suppl. 2009;195:S63-S67. doi:10.192/bjp.195.52.s63 PubMed
18. Diaz E, Woods SW, Rosenheck RA. Effects of ethnicity on psychotropic medications adherence. Community Ment Health J. 2005;41(5):521-537. doi:10.107/s10597-05-6359-x PubMed (Pubitemid 41243115)
19. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542-1550. doi:10.408/JCP.v67n108 PubMed (Pubitemid 44787436)
20. Mark TL, Palmer LA, Russo PA, et al. Examination of treatment pattern differences by race. Ment Health Serv Res. 2003;5(4):241-250. doi:10.1023/A:1026281890 PubMed (Pubitemid 37483548)
21. Chabungbam G, Avasthi A, Sharan P. Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci. 2007;61(6):587-593. doi:10.1/j.140-1819.207.0172.x PubMed (Pubitemid 350233479)
22. Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatr Serv. 1997;48(1):82-85. PubMed (Pubitemid 27024058)
23. Macpherson R, Jerrom B, Hughes A. Relationship between insight, educational background and cognition in schizophrenia. Br J Psychiatry. 1996;168(6):718-722. doi:10.192/bjp.168.6.718 PubMed
24. Kelly DL, Dixon LB, Kreyenbuhl JA, et al. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J Clin Psychiatry. 2006;67(9):1404-1411. doi:10.408/JCP.v67n091 PubMed (Pubitemid 44583388)
25. Walkup JT, McAlpine DD, Olfson M, et al. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry. 2000;61(5):344-348. doi:10.408/JCP.v61n0504 PubMed (Pubitemid 30345935)
26. Ascher-Svanum H, Zhu B, Faries D, et al. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(7):1114-1123. doi:10.408/JCP.v67n0715 (Pubitemid 44230884)